Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,023.80 -15.71 (-1.51%)

Official Closing Price Updated: 6:30 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine ↗

January 07, 2026

Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.

Via Investor's Business Daily

Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal ↗

January 07, 2026

Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40%.

Via Investor's Business Daily

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Via MarketMinute

Topics Economy

Eli Lilly Stock Rises After Hours On UBS ‘Buy’ Call Ahead Of Oral Obesity Pill Launch — GLP-1 Battle With Novo Heats Up ↗

January 06, 2026

Via Stocktwits

Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal ↗

January 07, 2026

Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction.

Via Stocktwits

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Via The Motley Fool

The Valuation Wall: Nasdaq Momentum Stalls as the 'Great Rotation' of 2026 Takes Hold

January 07, 2026

The relentless surge that propelled the technology sector to historic heights throughout 2024 and 2025 has hit a significant roadblock in the opening week of 2026. As of January 7, 2026, the tech-heavy...

Via MarketMinute

Topics Artificial Intelligence Economy

The Great Rotation: How the 2026 Market Rally Outgrew the 'Magnificent Seven'

January 07, 2026

As the first week of trading in 2026 comes to a close, the S&P 500 has once again shattered records, crossing the 7,500 threshold with a momentum that feels fundamentally different from the...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

This Could Be Key to Pfizer's Turnaround in 2026 ↗

January 07, 2026

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition ↗

January 07, 2026

Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.

Via Benzinga

Discover which S&P500 stocks are making waves on Wednesday. ↗

January 07, 2026

Via Chartmill

The Alpha Renaissance: Goldman Sachs Reports Record Hedge Fund Gains in 2025

January 07, 2026

In a landmark year for active management, Goldman Sachs (NYSE: GS) has released its comprehensive 2025 year-end report, revealing that the hedge fund industry staged a dramatic comeback, delivering...

Via MarketMinute

Topics Artificial Intelligence Economy

Why Did Eli Lilly Shares Surge Today? Key Factors ↗

January 07, 2026

Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 billion research partnership.

Via Talk Markets

Eli Lilly (LLY) Stock Is Up, What You Need To Know

January 07, 2026

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in...

Via StockStory

Topics Artificial Intelligence

My Top 5 Stocks to Buy in Early 2026 ↗

January 07, 2026

These companies are leaders in their fields.

Via The Motley Fool

Topics Artificial Intelligence

Ventyx (VTYX) Shares Soar 62.5% Overnight, Here's What's Going On With This Trending Stock ↗

January 06, 2026

Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.

Via Benzinga

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

January 06, 2026

Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.

Via The Motley Fool

Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗

January 06, 2026

Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem?

Via The Motley Fool

Topics Intellectual Property

Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover ↗

January 06, 2026

Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company.

Via Investor's Business Daily

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Via MarketMinute

Topics Economy

S&P 500 Shatters Records: Index Crosses 6,944 as Tech Giants and Healthcare Titans Lead the Charge

January 06, 2026

The S&P 500 reached a historic milestone on January 6, 2026, closing at a new all-time high of 6,944.82. This 0.6% gain on the first full trading week of the year signals a powerful continuation of the...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Ventyx Biosciences Stock Jumps On Reports Of Eli Lilly Buyout ↗

January 06, 2026

A deal for Ventyx could be announced imminently, the Wall Street Journal reported, citing people familiar with the matter.

Via Stocktwits

Eli Lilly Inks Deal With Nimbus Therapeutics To Find New Obesity Drug With AI ↗

January 06, 2026

Under the deal, Nimbus is eligible to receive up to $1.3 billion.

Via Stocktwits

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy Government

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗

January 06, 2026

Eli Lilly offers investors safety and growth.

Via The Motley Fool

Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss ↗

January 06, 2026

Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.

Via Investor's Business Daily

Motley Fool Money: Stock Market Naughty and Nice List ↗

January 06, 2026

There were nice companies and great CEOs in 2025, but also some duds. We discuss the stocks on each list and end by going shopping for stocks.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗

January 06, 2026

Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.